Phase I clinical trial of safety of L-serine for ALS patients.

@article{Levine2017PhaseIC,
  title={Phase I clinical trial of safety of L-serine for ALS patients.},
  author={Todd D. Levine and Robert G. Miller and Walter G. Bradley and Dan H. Moore and David S. Saperstein and Lynne E Flynn and Jonathan S. Katz and Dallas A Forshew and J S Metcalf and Sandra Anne Banack and Paul Alan Cox},
  journal={Amyotrophic lateral sclerosis & frontotemporal degeneration},
  year={2017},
  volume={18 1-2},
  pages={
          107-111
        }
}
  • Todd D. Levine, Robert G. Miller, +8 authors Paul Alan Cox
  • Published in
    Amyotrophic lateral sclerosis…
    2017
  • Medicine
  • We performed a randomized, double-blind phase I clinical trial for six months on the effects of oral L-serine in patients with ALS. The protocol called for enrollment of patients with a diagnosis of probable or definite ALS, age 18-85 years, disease duration of less than three years and forced vital capacity (FVC) ≥ 60%. Patients were randomly assigned to four different oral twice-daily dose regimens (0.5, 2.5, 7.5, or 15 g/dose). Blood, urine and CSF samples, ALS Functional Rating Scale… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 16 CITATIONS

    Clinical and metabolic consequences of L-serine supplementation in hereditary sensory and autonomic neuropathy type 1C

    VIEW 5 EXCERPTS
    CITES BACKGROUND & RESULTS
    HIGHLY INFLUENCED

    l-Serine Reduces Spinal Cord Pathology in a Vervet Model of Preclinical ALS/MND

    L‐serine: a neglected amino acid with a potential therapeutic role in diabetes

    VIEW 1 EXCERPT
    CITES BACKGROUND